ERYP News and Press, Erytech Pharma S.A. From 04/25/22

ERYTECH Pharma (NASDAQ:ERYP) announced the sale of its US manufacturing facility to Catalent, a leading contract development and manufacturing organization in advanced therapies for a total consideration of $44.5M. Per the terms of an asset purchase pact, Catalent agreed to acquire ...

Biodesix (BDSX) +53%. Actinium Pharmaceuticals ATNM +44% on agreement with Immedica Pharma for conditioning agent. BioCardia BCDA +34% after FDA nod to begin trial of BCDA-04 in COVID patients. Aeglea BioTherapeutics AGLE +19% on filing seeking FDA approval of pe...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re diving into the biggest pre-market stock movers for Thursday that investors are going to want to keep track of today. Source: oneinchpunch/Shutterstock.com Pharmaceutical announcements, insider trading,...

Biopharmaceutical company Erytech Pharma (NASDAQ:ERYP) published positive results in the British Journal of Haematology from the phase 2 trial of its lead product candidate eryaspase for the treatment of acute lymphoblastic leukemia (ALL), a type of cancer of the blood and...

ERYTECH Pharma S.A. (ERYP) Q4 2021 Earnings Conference Call March 14, 2022 08:30 AM ET Company Participants Gil Beyen - Chief Executive Officer Dr. Iman El-Hariry - Chief Medical Officer Eric Soyer - Chief Financial and Chief Operating Officer Conference Call Participants Boris Peaker - Cowen...

The following slide deck was published by ERYTECH Pharma S.A. in conjunction with their 2021 Q4 earnings call. For further details see: ERYTECH Pharma S.A. 2021 Q4 - Results - Earnings Call Presentation

Gainers: Zhongchao (NASDAQ:ZCMD) +35%. Moderna (NASDAQ:MRNA) +15%. ERYTECH Pharma (NASDAQ:ERYP) +14%. Allied Healthcare Products (NASDAQ:AHPI) +13%. 4D pharma (NASDAQ:LBPS) +13%. Losers: Nektar Therapeutics (NASDAQ:NKTR) -53%. MultiPlan (NYSE:MPLN) -26%. ...

Erytech Pharma press release (NASDAQ:ERYP): Q4 as of December 31, 2021, ERYTECH had cash and cash equivalents totaling ~$38.1M, compared with €44.4M as of December 31, 2020 and €38.0M on September 30, 2021. The Company believes that its current cash position, without considering...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

US Ecology ECOL +23% Republic Services is said in talks to purchase US Ecology. Enphase Energy ENPH +22% on Q4 results. ERYTECH Pharma (NASDAQ:ERYP) +13% expands patent portfolio for the treatment of rare metabolic diseases. Biofrontera (NASDAQ:BFRA) +12%. AVROBIO (NASDAQ:...